Acute left ventricular dysfunction following gemtuzumab ozogamicin in two children with AML
Kevin McNerney1; Katelyn Oranges1, Alix Seif1,2, Benjamin Oshrine3, Kelly Getz2, Richard Aplenc1,2*
1Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA, 19104
2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104
3Johns Hopkins All Children’s Hospital, St. Petersburg, FL, 33701
*Correspondence to:
Richard Aplenc, MD, PhD, Division of Oncology, Children’s Hospital of Philadelphia, 3501 Civic Center Blvd, Room 4018, Philadelphia, PA 19104. Tel: 267-426-7252, Email: aplenc@email.chop.edu
Text Word Count: 1200
Abstract Word Count: 84
Brief Running Title: Gemtuzumab and cardiotoxicity in pediatric AML
Tables: 1
Figures: 1